{
  "filename": "38---A-24-Year-Old-Female-Globetrotter-With-Strange_2022_Clinical-Cases-in-T.pdf",
  "markdown_path": "./Processed/markdown/38---A-24-Year-Old-Female-Globetrotter-With-Strange_2022_Clinical-Cases-in-T.md",
  "images": [
    {
      "page": 2,
      "path": "./Processed/images/38---A-24-Year-Old-Female-Globetrotter-With-Strange_2022_Clinical-Cases-in-T/38---A-24-Year-Old-Female-Globetrotter-With-Strange_2022_Clinical-Cases-in-T_p2_img1.jpeg"
    }
  ],
  "table_text": "| Neuroimaging Stage | Biology | Anticysticercal Treatment |\n|---|---|---|\n| Isointense/isodense to CSF, no contrast enhancement | Vesicular Viable, non-immunogenic, can persist asymptomatically for years | 1-2 cysts Albendazole∗ + steroids for 10-14 days |\n| Enhanced wall (‘ring enhancement’) on contrast imaging, surrounding oedema | Colloidal Viable but degenerating, immunogenic | >2 cysts Albendazole∗ + Praziquantel∗ + steroids for 10-14 days |\n| Thickened retracted cyst without oedema | Granulo-nodular Degenerated | No anthelmintic treatment |\n| Calcification | Calcified Final involuted stage | |\n∗ diffuse cerebral oedema is a contraindication for antihelminthic treatment",
  "table_source": "/Users/macintoshhd/Downloads/Project-Dr.Khanh/Clinical-RAG/Processed/out_all_structured/38---A-24-Year-Old-Female-Globetrotter-With-Strange_2022_Clinical-Cases-in-T-tables.md"
}